BioVision, Inc.
155 S. Milpitas Blvd, Milpitas, CA 95035 USA
Toll Free: 800-891-9699 | Email: tech@biovision.com

Anti-diabetic Compounds & Obesity Peptides

Novel approaches for Diabetes & Obesity Research

Diabetes & obesity has reached epidemic proportions worldwide and is a major contributor to the global burden of various other chronic diseases such as coronary artery diseases, myocardial infarction, hypertension, dyslipidemia and number of other complicated disorders. Diabetes mellitus is clinically characterized by a marked increase in blood glucose levels and is associated with mild hyperlipidemia & obesity is the accumulation of body fat to the extent where it leads to reduced life expectancy & other severe health problems including type 2 diabetes. Significant amount of work has been done towards the development of preventive and therapeutic strategies against diabetes & obesity. Some of the recent research approaches include receptors targeting, islet cell transplantation, gene expression profiling, glucagon-like peptide-1, dipeptidyl peptidase IV inhibitors, insulin therapy, modulators of peroxisome proliferator-activated receptors (PPAR), glucagon receptor antagonists, insulin analogues, ghrelin, peptide YY and combination therapies.

BioVision offers diverse range of high-quality anti-diabetic compounds & obesity peptides for both in vitro & in vivo research.

Name	Cat. #
Ciglitazone	1695-5
Diprotin A	2191-5, 25
Diprotin B	2192-5, 25
DPP IV Inhibitor, K 579	1963-1, 5
DPP IV Inhibitor, NVP DPP 728	1964-1, 5
Fatostatin	2035-5, 25
Glibenclamide	1878-500, 1000
Human Ghrelin	4990-100, 1000
Linagliptin	2240-50, 250
Metformin, Hydrochloride	1691-5G
Obestatin (Human)	1705-500
Phenformin hydrochloride	1889-100, 1000
Pioglitazone	1877-5, 25, 100
Rosiglitazone	1559-5, 50, 100
Sitagliptin Phosphate Monohydrate	1757-100, 1G
Skyrin, Talaromyces sp.	2043-1
Troglitazone	1696-5
Vicriviroc Malate	1599-1, 5
Vildagliptin	2188-10, 50